Dianthus Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.71 | -$0.23 | -$0.44 |
| Q2 2024 | 1 | -$0.89 | -$0.28 | -$0.55 |
| Q3 2024 | 3 | -$0.97 | -$0.31 | -$0.59 |
| Q4 2024 | 8 | -$1.14 | -$0.58 | -$0.85 |
| Q1 2025 | 5 | -$1.17 | -$0.60 | -$0.88 |
| Q2 2025 | 4 | -$1.52 | -$0.48 | -$0.93 |
| Q3 2025 | 4 | -$1.53 | -$0.48 | -$0.94 |
| Q4 2025 | 4 | -$1.50 | -$0.47 | -$0.92 |
Dianthus Therapeutics, Inc. Earnings Date And Information
Dianthus Therapeutics, Inc. last posted its earnings results on Thursday, November 7th, 2024. The company reported $-0.74 earnings per share for the quarter, missing analysts' consensus estimates of $-0.59 by $0.15. The company had revenue of 2.17 M for the quarter and had revenue of 2.83 M for the year. Dianthus Therapeutics, Inc. has generated $-8 earnings per share over the last year ($-8.4517 diluted earnings per share) and currently has a price-to-earnings ratio of -12.04. Dianthus Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 20th, 2025 based on prior year's report dates.
Dianthus Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/07/2024 | Q3 2024 | -$0.59 | -$0.74 | -0.15 | $741,143 | $2.17 M |
| 08/08/2024 | Q2 2024 | -$0.50 | -$0.51 | -0.01 | $368,857 | $1.86 M |
| 05/09/2024 | Q1 2024 | -$0.43 | -$0.54 | -0.11 | $874,000 | |
| 03/21/2024 | Q4 2023 | -$1.11 | -$2.33 | -1.22 | $457,000 | |
| 09/29/2023 | Q3 2023 | -$3.78 | $250,000 | $924,000 | ||
| 08/03/2023 | Q2 2023 | -$0.19 | -$0.87 | -0.68 | $969,000 | |
| 03/29/2023 | Q1 2023 | -$7.70 | $476,000 | |||
| 12/30/2022 | Q4 2022 | -$5.32 | $1.18 M | |||
| 09/29/2022 | Q3 2022 | -$4.34 | $1.17 M | |||
| 08/04/2022 | Q2 2022 | -$4.70 | $0 | |||
| 05/16/2022 | Q1 2022 | -$6.25 | $0 | |||
| 03/08/2022 | Q4 2021 | -$5.25 | $0 | |||
| 11/04/2021 | Q3 2021 | -$4.76 | $0 | |||
| 08/05/2021 | Q2 2021 | -$5.04 | $0 | |||
| 05/06/2021 | Q1 2021 | -$5.76 | $0 | |||
| 03/03/2021 | Q4 2020 | -$5.99 | $0 | |||
| 11/05/2020 | Q3 2020 | -$5.86 | $0 | |||
| 08/06/2020 | Q2 2020 | -$7.71 | $0 | |||
| 05/07/2020 | Q1 2020 | -$8.13 | $0 | |||
| 03/03/2020 | Q4 2019 | -$9.52 | $0 |
Dianthus Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is Dianthus Therapeutics, Inc.'s earnings date?
Dianthus Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 20th, 2025 based off last year's report dates.
-
How can I listen to Dianthus Therapeutics, Inc.'s earnings conference call?
The conference call for Dianthus Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read Dianthus Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Dianthus Therapeutics, Inc.'s latest earnings report can be read online.
-
How much revenue does Dianthus Therapeutics, Inc. generate each year?
Dianthus Therapeutics, Inc. (:DNTH) has a recorded annual revenue of $2.83 M.
-
How much profit does Dianthus Therapeutics, Inc. generate each year?
Dianthus Therapeutics, Inc. (:DNTH) has a recorded net income of $2.83 M. Dianthus Therapeutics, Inc. has generated $-8.4517 earnings per share over the last four quarters.
-
What is Dianthus Therapeutics, Inc.'s price-to-earnings ratio?
Dianthus Therapeutics, Inc. (:DNTH) has a price-to-earnings ratio of -12.04 and price/earnings-to-growth ratio is -0.18.
